Safety and efficacy of apatinib for metastatic kidney cancer

A recent study coming out of China has identified a new oral tyrosine kinase inhibitor (TKI) with promising safety and efficacy for metastatic renal cell carcinoma (RCC). Anti-angiogenic treatments, such as the TKIs sunitinib, pazopanib and axitinib, play an important role in the treatment of metastatic RCC. A new TKI called apatinib targets the vascular […]

read more

Complete response to immune checkpoint inhibitors in kidney cancer patients

A recent meta-analysis of 6 randomised phase II and III studies looked at complete response rates to immune checkpoint inhibitors in patients with renal cell carcinoma. Data from the following 6 studies were analysed; CheckMate 214, CheckMate 025, KEYNOTE-426, Javelin Renal 101, IMmotion150, and IMmotion151, which included a total of 4531 patients. The incidence of […]

read more

Comparison of first-line immunotherapy combinations for metastatic kidney cancer

This meta-analysis of first-line immunotherapy trials was published in the journal Cancers last month. The analysis compares the three active first-line treatment combinations for metastatic renal cell carcinoma (RCC) and provides guidance in the selection of treatment for previously untreated patients. Three combination treatments were compared; pembrolizumab plus axitinib, avelumab plus axitinib and nivolumab plus […]

read more

Ipilimumub plus nivolumab combination after prior treatment with immune checkpoint inhibitors

This retrospective study published in the Journal of Clinical Oncology looked at the response rates and progression-free survival of metastatic renal cell carcinoma (RCC) patients treated with a combination of ipilimumab plus nivolumab after previous treatment with an immune checkpoint inhibitor. Forty-five patients with metastatic RCC who had already been treated with an immune checkpoint […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more

Promising efficacy and safety of seleno-L-methionine plus axitinib in advanced kidney cancer

Data from a recent phase I study of seleno-L-methionine in combination with axitinib (Inlyta) as treatment for patients with previously treated or relapsed clear cell renal cell carcinoma (ccRCC) were presented at the American Urological Association (AUA) Virtual Experience meeting over the weekend. There were 15 patients in the study with ccRCC whose disease had […]

read more

Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer

Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating nivolumab (Opdivo) in combination with cabozantinib (Cabometyx) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC) were released today. These top-line results were positive for the combination treatment, which improved progression-free survival, overall survival and objective response rate compared to sunitinib. […]

read more

Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma

In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]

read more

ASCO GU 2020: VEGF tyrosine kinase inhibitors as second-line treatment after immunotherapy for advanced kidney cancer

A retrospective analysis of data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) was presented at the American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco from 13-15 February. The analysis looked at response rates and survival of metastatic renal cell carcinoma (RCC) patients who had been treated with […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more
Showing 1 to 10 of 14 results
  TOP